Skip to main content
Top
Published in: Medical Oncology 5/2012

01-12-2012 | Letter to the Editor

Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion

Authors: Elisabeth Krexner, Anika Stickler, Christian Prainer, Josef Finsterer

Published in: Medical Oncology | Issue 5/2012

Login to get access

Excerpt

Oxaliplatin is a platinum derivative, which is increasingly applied in chemotherapy of various malignancies, most frequently gastrointestinal malignancies [1]. Oxaliplatin may cause a number of adverse reactions, frequently neurological in nature (neurotoxicity), which may be acute or chronic [13]. Acute neurotoxicity manifests as sensory disturbances of the hands, feet, pharynx or larynx, or throat or jaw tightness, triggered or exacerbated by cold [1, 3, 4]. More rare acute neurological side effects include blepharoptosis or neuromyotonia [1, 5]. Repetitive nerve stimulation may show an abnormal decremental response and needle EMG neuromyotonic discharges [6]. Neurotoxicity from oxaliplatin is usually transient and reversible with complete recovery [7]. Chronic neurotoxicity of oxaliplatin includes sensory neuropathy, hyperexcitability syndrome, muscle cramps, dysarthria, ptosis, or visual field defects [4]. …
Literature
1.
go back to reference Lau SC, Shibata SI. Blepharoptosis following oxaliplatin administration. J Oncol Pharm Pract. 2009;15:255–7.PubMedCrossRef Lau SC, Shibata SI. Blepharoptosis following oxaliplatin administration. J Oncol Pharm Pract. 2009;15:255–7.PubMedCrossRef
2.
go back to reference Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23:200–5.PubMedCrossRef Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23:200–5.PubMedCrossRef
3.
go back to reference Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767–74.PubMedCrossRef Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767–74.PubMedCrossRef
4.
go back to reference Saif MW, Hashmi S. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:349–54.PubMedCrossRef Saif MW, Hashmi S. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:349–54.PubMedCrossRef
5.
go back to reference Saadati H, Saif MW. Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer. JOP. 2009;10:459–61.PubMed Saadati H, Saif MW. Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer. JOP. 2009;10:459–61.PubMed
6.
go back to reference Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29:387–92.PubMedCrossRef Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29:387–92.PubMedCrossRef
7.
go back to reference La Verde N, Garassino MC, Spinelli G, Scanni A, Sburlati P, Farina G, Labianca R. Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis. 2007;39:1041.PubMedCrossRef La Verde N, Garassino MC, Spinelli G, Scanni A, Sburlati P, Farina G, Labianca R. Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis. 2007;39:1041.PubMedCrossRef
8.
go back to reference Teagarden CM, Picardo CW. Betamethasone-induced hypokalemic periodic paralysis in pregnancy. Obstet Gynecol. 2011;117:433–5.PubMedCrossRef Teagarden CM, Picardo CW. Betamethasone-induced hypokalemic periodic paralysis in pregnancy. Obstet Gynecol. 2011;117:433–5.PubMedCrossRef
9.
go back to reference Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol. 2011;16:244–9.PubMedCrossRef Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol. 2011;16:244–9.PubMedCrossRef
10.
go back to reference Gutierrez M, Silveri F, Bertolazzi C, Giacchetti G, Tardella M, Di Geso L, Filippucci E, Grassi W. Gitelman syndrome associated with chondrocalcinosis: description of two cases. Reumatismo. 2010;62:60–4.PubMed Gutierrez M, Silveri F, Bertolazzi C, Giacchetti G, Tardella M, Di Geso L, Filippucci E, Grassi W. Gitelman syndrome associated with chondrocalcinosis: description of two cases. Reumatismo. 2010;62:60–4.PubMed
Metadata
Title
Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion
Authors
Elisabeth Krexner
Anika Stickler
Christian Prainer
Josef Finsterer
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0264-2

Other articles of this Issue 5/2012

Medical Oncology 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.